203 related articles for article (PubMed ID: 24818166)
1. The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy.
Han S; Jin G; Wang L; Li M; He C; Guo X; Zhu Q
J Immunol Res; 2014; 2014():268479. PubMed ID: 24818166
[TBL] [Abstract][Full Text] [Related]
2. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
[TBL] [Abstract][Full Text] [Related]
3. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
[TBL] [Abstract][Full Text] [Related]
4. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.
Gold DV; Newsome G; Liu D; Goldenberg DM
Mol Cancer; 2013 Nov; 12(1):143. PubMed ID: 24257318
[TBL] [Abstract][Full Text] [Related]
5. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
Gold DV; Schutsky K; Modrak D; Cardillo TM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3929S-37S. PubMed ID: 14506191
[TBL] [Abstract][Full Text] [Related]
6. Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4.
Gold DV; Cardillo T; Goldenberg DM; Sharkey RM
Crit Rev Oncol Hematol; 2001; 39(1-2):147-54. PubMed ID: 11418312
[TBL] [Abstract][Full Text] [Related]
7. Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer.
Mariani G; Molea N; Bacciardi D; Boggi U; Fornaciari G; Campani D; Salvadori PA; Giulianotti PC; Mosca F; Gold DV
Cancer Res; 1995 Dec; 55(23 Suppl):5911s-5915s. PubMed ID: 7493369
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
[TBL] [Abstract][Full Text] [Related]
9. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer.
Cardillo TM; Blumenthal R; Ying Z; Gold DV
Int J Cancer; 2002 Jan; 97(3):386-92. PubMed ID: 11774294
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer.
Cardillo TM; Ying Z; Gold DV
Clin Cancer Res; 2001 Oct; 7(10):3186-92. PubMed ID: 11595713
[TBL] [Abstract][Full Text] [Related]
11. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine.
Karacay H; Sharkey RM; Gold DV; Ragland DR; McBride WJ; Rossi EA; Chang CH; Goldenberg DM
J Nucl Med; 2009 Dec; 50(12):2008-16. PubMed ID: 19949026
[TBL] [Abstract][Full Text] [Related]
12. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin.
Gold DV; Lew K; Maliniak R; Hernandez M; Cardillo T
Int J Cancer; 1994 Apr; 57(2):204-10. PubMed ID: 7512537
[TBL] [Abstract][Full Text] [Related]
13. Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer.
Alisauskus R; Wong GY; Gold DV
Cancer Res; 1995 Dec; 55(23 Suppl):5743s-5748s. PubMed ID: 7493339
[TBL] [Abstract][Full Text] [Related]
14. Imaging of pancreatic adenocarcinoma with radiolabeled monoclonal antibodies.
Mariani G
Ann Oncol; 1999; 10 Suppl 4():37-40. PubMed ID: 10436782
[TBL] [Abstract][Full Text] [Related]
15. Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer.
Liu D; Chang CH; Gold DV; Goldenberg DM
Oncotarget; 2015 Feb; 6(6):4274-85. PubMed ID: 25595893
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4.
Gold DV; Cardillo T; Vardi Y; Blumenthal R
Int J Cancer; 1997 May; 71(4):660-7. PubMed ID: 9178823
[TBL] [Abstract][Full Text] [Related]
17. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
[TBL] [Abstract][Full Text] [Related]
18. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Picozzi VJ; Ramanathan RK; Lowery MA; Ocean AJ; Mitchel EP; O'Neil BH; Guarino MJ; Conkling PR; Cohen SJ; Bahary N; Frank RC; Dragovich T; Bridges BB; Braiteh FS; Starodub AN; Lee FC; Gribbin TE; Richards DA; Lee M; Korn RL; Pandit-Taskar N; Goldsmith SJ; Intenzo CM; Sheikh A; Manzone TC; Horne H; Sharkey RM; Wegener WA; O'Reilly EM; Goldenberg DM; Von Hoff DD
Eur J Cancer; 2015 Sep; 51(14):1857-64. PubMed ID: 26187510
[TBL] [Abstract][Full Text] [Related]
19. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies.
Zhu H; Baxter LT; Jain RK
J Nucl Med; 1997 May; 38(5):731-41. PubMed ID: 9170438
[TBL] [Abstract][Full Text] [Related]
20. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.
Gold DV; Modrak DE; Ying Z; Cardillo TM; Sharkey RM; Goldenberg DM
J Clin Oncol; 2006 Jan; 24(2):252-8. PubMed ID: 16344318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
